Follow-up After Surgery for Testicular Cancer
A legfontosabb adatok
- Ki végzi
- Erasmus Medical Center
- Hol
- Hollandia1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 145 fő, tervezett
- Kezdés
- 2022. nov. 30.
- Várható befejezés
- 2030. dec.
- A vizsgálat típusa
- Megfigyeléses, 4 csoport
- A regiszteradat frissítve
- 2023. február 23.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for men treated for testicular cancer that has not spread far, less than 3 months ago. It tests a follow-up plan led by patients at home.
- Életkor
- 18 years and older.
- Nem
- Men only.
- A betegség stádiuma
- Testicular germ cell cancer confirmed by tissue test, with no distant spread. Treatment was meant to remove all of the disease. Groups: non-seminoma stage I low risk, non-seminoma stage I high risk, or seminoma or non-seminoma in complete remission after chemotherapy. Scans must show no swollen lymph nodes or spread.
- Korábbi kezelés
- Treated less than 3 months ago. Stage I high risk: must have finished one cycle of Bleomycin, etoposide and platinum (BEP). People who had lymph node removal surgery after testicle removal can join if the scan shows no disease left. Must be scheduled for, or already in, follow-up after surgery.
- Biomarker vagy leletérték
- Three blood tests in a row with normal tumour markers.
A részvétel fő kizáró okai
- LDH level above 248 U/L before surgery.
- Taking part in another study that needs scans of the belly or chest yearly or more often.
- Another illness or cancer that needs scans of the belly or chest yearly or more often.
- Unable to fill in questionnaires because of not reading or not knowing enough Dutch.
A regiszter feltételei, szó szerint
Mind a 16 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 18 years
- Histologically confirmed testicular cancer without distant metastasis and treated with curative intent less than 3 months ago:; Non-seminomatous germ cell tumours, stage I low risk:
- No lymphadenopathy or metastases on the postoperative scan
- Three consecutive blood drawings with normal tumour markers
- Patients undergoing lymph node dissection as a second curative operation after an orchiectomy, can also be included in case that the postoperative scan shows no residual disease or metastases; Non-seminomatous germ cell tumours, stage I high risk:
- After completion of one cycle of Bleomycin, etoposide and platinum (BEP)
- Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers
- No lymphadenopathy or metastases on the CT scan after completion of chemotherapy; Seminomatous or non-seminomatous germ cell tumours (after chemotherapy) with complete remission
- Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers
- No lymphadenopathy or metastases on the CT scan after completion of chemotherapy
- Scheduled or currently undergoing postoperative surveillance according to national and European guidelines
- Signed informed consent
Ki nem vehet részt
- Patients with comorbidity or other malignancy that requires imaging of the abdomen and/or thorax every year or more frequent
- Patients with aberrant levels of LDH preoperatively (LDH >248 U/L)
- Patients enrolled in other studies that require strict adherence to any specific follow-up practice with regular imaging - yearly or more frequent - of the abdomen and/or thorax
- Inability to complete the questionnaires due to illiteracy and/or insufficient proficiency of the Dutch language
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The currently developed implementation study aims to evaluate if a patient-led home-based follow-up approach is successful, improves quality of life, reduces anxiety and lessens fear of cancer recurrence during the years after treatment of certain types of testicular cancer.
A vizsgálat 4 csoportja
- Non-seminomatous germ cell tumours, stage I low risk
No lymphadenopathy or metastases on the postoperative scan. Three consecutive blood drawings with normal tumour markers. Patients undergoing lymph node dissection as a second curative operation after an orchiectomy, can also be included in case that the postoperative scan shows no residual disease or metastases.
- Non-seminomatous germ cell tumours, stage I high risk
After completion of one cycle of Bleomycin, etoposide and platinum (BEP). Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers. No lymphadenopathy or metastases on the CT scan after completion of chemotherapy.
- Seminomatous germ cell tumours (after chemotherapy) with complete remission.
Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers. No lymphadenopathy or metastases on the CT scan after completion of chemotherapy.
- Non-seminomatous germ cell tumours (after chemotherapy) with complete remission.
Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers. No lymphadenopathy or metastases on the CT scan after completion of chemotherapy.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Follow-up After Surgery for Testicular Cancer: the Prospective, Single Centre FUTURE-testis Implementation Study
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2023. február 23.